{
  "id": 20911381,
  "title": "STAT+: Pharmalittle: We’re reading about Sanofi eyeing Insmed, AI speeding drug development, and more",
  "url": "https://urgent.news/2026/11/20/stat-pharmalittle-were-reading-about-sanofi-eyeing-insmed-ai-speeding",
  "topic": "ai",
  "section": "AI",
  "published": "2026-11-20T14:16:35.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/pharmalot/2026/11/20/sanofi-eyeing-insmed-ai-speeding-drug-development/"
  },
  "original_language": "en",
  "account": "AI has accelerated the early-stage drug development process for major pharmaceutical companies in 2023, potentially reducing the time to bring new molecules into clinical trials by up to 50%, according to Reuters. Leaders at Bristol Myers Squibb, Novartis, Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca have shifted their focus from mundane tasks, such as regulatory filing preparation, to leveraging AI for designing molecules, assessing promising candidates, and identifying potential safety issues.\n\nSeveral of the largest pharmaceutical firms have informed a Congressional committee that they do not intend to establish new clinical trial sites in China's Xinjiang region or at hospitals associated with the Chinese military. This revelation was made by the House Select Committee on China, which initiated investigations into five companies—Merck, Eli Lilly, AbbVie, Pfizer, and Bristol Myers Squibb—due to concerns about intellectual property vulnerabilities, military connections, and ethical standards at trial locations in sensitive areas of China.",
  "summary": "Sanofi weighs an Insmed takeover, the FDA slams J&J over misleading bladder cancer drug claims, and more pharma news:",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}